Denmark's biotech SMEs have a valuable growth generating role  

Morgan Stanley conference concludes that pharma heavyweights need biotech SMEs to ensure future growth

The major pharmaceutical companies have a general need for small and medium sized biotech companies to ensure future growth. That was one of the main conclusions of a Morgan Stanley health sector conference held last week, reports financial newspaper Børsen. However to be attractive as potential cooperation partners, biotech SMEs must have phase 2 or phase 3 products in the pipeline says Jyske Bank, which participated in the conference. These pipeline products are highly sought after, a fact evidenced by an agreement made between NeuroSearch and Boehringer Ingelheim, which Jyske Bank describes as "very lucrative".

Denmark is fortunate in having a dynamic biotech cluster in what is now called Medicon Valley, one of the three largest medical and biotechnological growth centres in Europe. Besides being home to more than 60% of Scandinavia’s pharmaceutical industry heavyweights, Medicon Valley also has over 200 biotech SMEs. In the biotech industry, the region is reputed to have the highest turnover per capita in the world.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×